There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > ACADEMIA
ACADEMIA
- Jikei Concludes Event Data Unnatural in Diovan Study
December 15, 2014
- British Medical Journal Retracts Sub-Analysis Paper of VART Study
December 11, 2014
- Cancer Researchers Call for Academia-Industry Collaboration via Japan NIH
December 9, 2014
- 22 Seeds Supported by Drug Discovery Support Network So Far: Dr Kurebayashi of NIBIO
December 9, 2014
- AIDS Treatment Extends Lives, but Many Problems Remain: Dr Mitsuya
December 1, 2014
- J-ARF Moving Into Full Gear as Academic Research Organization
December 1, 2014
- Next Year to See “Dawn of New Age” of Interferon-Free Hepatitis C Treatment: Dr Kumada
November 28, 2014
- Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official
November 27, 2014
- J-CLEAR’s Kuwajima Criticizes Plan to Legally Regulate Clinical Research
November 12, 2014
- ICH-GCP Compliance Obligatory for Clinical Studies Conducted by Chiba University
October 28, 2014
- Chiba University Issues Warning to Prof. Involved in VART Study
October 28, 2014
- JSH to Draft Guidelines on Clinical Research with Company Funding
October 21, 2014
- St. Marianna Hospital Elbows Drug Makers to Reveal Detailing Costs Embedded in Drug Prices
October 10, 2014
- Japanese Society of Hypertension Announces Resignation of President
October 1, 2014
- Rivaroxaban as Safe and Effective as Standard Therapy in Japanese DVT Patients: J-EINSTEIN DVT Study
September 30, 2014
- Safety and Efficacy of Secukinumab Confirmed for Psoriasis in Japanese Patients
September 24, 2014
- Dr Yui Poses Questions on Dabigatran Analysis Model on BMJ
September 9, 2014
- Prof. Komuro to Issue Objection to Chiba University in Wake of Second Retraction Request Related to VART Study
September 9, 2014
- Kyoto University, Astellas Aim to Develop Immunological Disease Cures, 11 Target Molecules Now under Screening
August 21, 2014
- Chiba Univ. Once Again Advises Authors to Withdraw Papers from VART Study
August 19, 2014
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…